See where third-party promotion departs from the reference material your team has approved. Put the page, wording and review context in front of the people who can decide what happens next.
Discuss pharma & biotech monitoring ↗A product launch, new publisher campaign, agency handover or change to approved messaging creates a new set of external pages to check.
A partner expands an approved claim or introduces a use not covered by your reference pack.
Capture the wording and the reference it differs from; send it to the designated promotional reviewer.
A shorter page, social caption or comparison removes a qualification required by your approved wording.
Show the captured context so a reviewer can distinguish an omission from an acceptable variation.
Publicly accessible content appears to promote a prescription medicine, or content intended for professionals appears on a public page.
Record how the content was accessed and flag it against the rules configured for that market. This is not proof of an individual visitor’s status.
A publisher still uses wording from a superseded campaign or reference version.
Identify the affected URL and the current reference supplied by your team.
A contracted publisher links to another site, or an independent page mentions your brand.
Keep known partners separate from observed associations; confirm responsibility before requesting a correction.
Configure these checks around your approved references, supported sources and market rules.
Give promotional reviewers a page-specific exception to assess, and give partner teams a documented correction to follow up. Brand teams can also see where relevant publishers cover competing products or topics.
Explore Marketing Compliance Explore Marketing IntelligenceIdentify the actual classification. Do not apply one promotional rule set to every medicine or health product.
Define the intended audience and observable access context. An open page and authorised professional content need different review scopes.
Agree the relevant market policy with your reviewers. A US campaign and UK public-facing promotion must not be treated as interchangeable.
Separate commissioned promotion, contracted partner activity and independent editorial mentions. An observed link does not establish commercial responsibility.
Your team approves the reference material and makes the final judgement. If content raises a safety concern or product complaint, follow your established safety process; do not rely on marketing monitoring as the intake or reporting system.
Treato supports post-publication marketing oversight. It does not approve promotional materials, make clinical judgements, replace medical/legal/regulatory review, certification or regulatory submissions, or provide a pharmacovigilance or product-complaint intake system.
See the review handoffThe prescription-medicine example separates the source observation from the reviewer’s decision, including whether the promotion should appear on that page at all.
Open the pharmaceutical exampleUK guidance prohibits advertising prescription-only medicines to the public, while permitting public advertising of non-prescription medicines subject to the applicable requirements. Read the MHRA guidance.
US prescription-drug advertising has a different framework: FDA describes requirements including truthful, non-misleading presentation and fair balance between effectiveness and risk information. Read the FDA’s OPDP FAQs.
For UK public-facing promotion, the ASA also explains why linked destinations and implied prescription-medicine references can matter. Read the ASA guidance.
These examples explain why your qualified reviewers define the policy. Treato does not interpret one universal regulatory rule or provide a compliance certificate.
Keep patient records, enquiry submissions and safety-case details out of the information you supply. Before monitoring starts, agree how incidental personal information, possible adverse events and product complaints will be handled through your own approved procedures. Standard marketing oversight is not a safety-intake, reporting or case-management system.
Distinguish a new reference from a new partner edit. Scope the medicine, audience, country and effective date together; a match against the wrong version is not a useful finding.
Bring a representative partner page and the wording you expect it to use. We will discuss the checks, coverage and outputs your team needs.
Talk to Treato A conversation about your partners, markets and priorities.